SBT-272


Mitochondria-targeted cardiolipin-stabilizing peptidomimetic with enhanced central nervous system penetration

A next-generation cardiolipin-binding peptidomimetic developed by Stealth BioTherapeutics as a brain-penetrant successor to elamipretide (SS-31), designed to restore mitochondrial structure and function in neurodegenerative disease with demonstrated preclinical neuroprotection in models of amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, Huntington’s disease, and ischemic stroke.

Abstract

SBT-272, also designated bevemipretide (International Nonproprietary Name), is a clinical-stage mitochondria-targeted peptidomimetic small molecule developed by Stealth BioTherapeutics as a structurally optimized successor to elamipretide (SS-31, MTP-131, Bendavia). The compound selectively binds cardiolipin, a diphosphatidylglycerol lipid exclusively localized to the inner mitochondrial membrane, where it stabilizes the organization of electron transport chain complexes into supercomplexes (respirasomes), promotes efficient oxidative phosphorylation, reduces mitochondrial reactive oxygen species generation, and prevents the cytochrome c/cardiolipin peroxidase activity that initiates apoptotic signaling. Relative to the first-generation elamipretide scaffold, SBT-272 demonstrates higher mitochondrial uptake, greater brain accumulation following subcutaneous administration, and improved systemic bioavailability in preclinical species, properties that position the compound for neurodegenerative disease indications where central nervous system exposure is a critical determinant of therapeutic effect.

The preclinical pharmacology of SBT-272 encompasses multiple neurodegenerative disease models. In TDP-43 mutant upper motor neuron cultures derived from the prpTDP-43(A315T) transgenic mouse, SBT-272 restored mitochondrial structural integrity, recovered mitochondrial motility in a dose-dependent manner, and improved axon outgrowth, a functional indicator of neuronal health, with effects superior to those of edaravone and AMX0035 in the same system [1]. Chronic in vivo treatment for sixty days in the same model significantly reduced astrogliosis, microgliosis, and TDP-43 pathology in the motor cortex [1]. In an alpha-synucleinopathy mouse model of Parkinson’s disease, daily subcutaneous SBT-272 attenuated dopaminergic neuron loss, reduced pathological alpha-synuclein burden, and suppressed neuroinflammatory markers [3]. Additional preclinical neuroprotective activity has been reported in models of frontotemporal lobar dementia, Huntington’s disease, and ischemic stroke [4].

Interim results demonstrated a pharmacokinetic profile consistent with preclinical allometric scaling predictions, plasma and projected brain exposures at doses anticipated to reach therapeutic concentrations based on preclinical efficacy thresholds, and a safety profile in which the most commonly reported adverse event was mild-to-moderate injection site reaction resolving within approximately 4 hours of dosing [5]. The United States Food and Drug Administration granted Orphan Drug Designation for SBT-272 for the treatment of amyotrophic lateral sclerosis in 2022 [4]. A separate development program for topical ocular bevemipretide (eye drops) in dry age-related macular degeneration has advanced through preclinical studies demonstrating approximately 4- to 6-fold higher retinal tissue concentrations compared to elamipretide, with a 13-week GLP toxicology study informing Phase 1 trial design [6, 7].

This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph